| 产品编号 | bs-2585R |
| 英文名称 | FOXF1 Rabbit pAb |
| 中文名称 | 叉头蛋白F1抗体 |
| 别 名 | AI450827; FKH L5; FKHL 5; FKHL5; FKHL5; Forkhead(Drosophila) like 5; forkhead(Drosophila)-like 5; forkhead(Drosophila)-like 5; forkhead box F1; forkhead box F1; Forkhead box protein F1; Forkhead drosophila homolog like 5; Forkhead like 5; Forkhead related activator 1; Forkhead related protein FKHL5; Forkhead related transcription factor 1; forkhead-related activator 1; forkhead-related activator 1; Forkhead-related protein FKHL5; Forkhead-related transcription factor 1; FOX F1; FOXF 1; foxf1; FOXF1_HUMAN; FREAC 1; FREAC-1; FREAC1; FREAC1; HFH 8; homolog-like 5; homolog-like 5; MGC105125. |
| 研究领域 | 免疫学 染色质和核信号 表观遗传学 |
| 抗体来源 | Rabbit |
| 克隆类型 | Polyclonal |
| 克 隆 号 | |
| 交叉反应 | Mouse (predicted: Human,Rat,Rabbit,Cow,Chicken,Dog) |
| 产品应用 | WB=1:500-2000
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理论分子量 | 40 kDa |
| 检测分子量 | |
| 细胞定位 | 细胞核 |
| 性 状 | Liquid |
| 浓 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human FOXF1: 285-379/379 |
| 亚 型 | IgG |
| 纯化方法 | affinity purified by Protein A |
| 缓 冲 液 | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| 保存条件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事项 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 产品介绍 |
This gene belongs to the forkhead family of transcription factors which is characterized by a distinct forkhead domain. The specific function of this gene has not yet been determined; however, it may play a role in the regulation of pulmonary genes as well as embryonic development. [provided by RefSeq, Jul 2008] Function: Probable transcription activator for a number of lung-specific genes. Subcellular Location: Nucleus (Probable). Tissue Specificity: Expressed in lung and placenta. DISEASE: Alveolar capillary dysplasia with misalignment of pulmonary veins (ACDMPV) [MIM:265380]: A rare developmental disorder characterized by abnormal development of the capillary vascular system in the lungs. Histological features include failure of formation and ingrowth of alveolar capillaries, medial muscular thickening of small pulmonary arterioles with muscularization of the intraacinar arterioles, thickened alveolar walls, and anomalously situated pulmonary veins running alongside pulmonary arterioles and sharing the same adventitial sheath. Less common features include a reduced number of alveoli and a patchy distribution of the histopathologic changes. Affected infants present with respiratory distress and the disease is fatal within the newborn period. Additional features include multiple congenital anomalies affecting the cardiovascular, gastrointestinal, genitourinary, and musculoskeletal systems, as well as disruption of the normal right-left asymmetry of intrathoracic or intraabdominal organs. ACDMPV is a rare cause of persistent pulmonary hypertension of the newborn, an abnormal physiologic state caused by failure of transition of the pulmonary circulation from the high pulmonary vascular resistance of the fetus to the low pulmonary vascular resistance of the newborn. Note=The disease is caused by mutations affecting the gene represented in this entry. Similarity: Contains 1 fork-head DNA-binding domain. SWISS: Q12946 Gene ID: 2294 Database links: Entrez Gene: 2294 Human Omim: 601089 Human SwissProt: Q12946 Human Unigene: 155591 Human |
| 产品图片 |
Sample:
Lane 1: Stomach (Mouse) Lysate at 40 ug
Lane 2: Lung (Mouse) Lysate at 40 ug
Lane 3: Urinary bladder (Mouse) Lysate at 40 ug
Lane 4: NIH/3T3 (Mouse) Cell Lysate at 30 ug
Primary: Anti-FOXF1 (bs-2585R) at 1/1000 dilution
Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution
Predicted band size: 40 kD
Observed band size: 50 kD
|
| 1、抗体溶解方法 | |
| 2、抗体修复方式 | |
| 3、常用试剂的配制 | |
| 4、免疫组化操作步骤 | |
| 5、免疫组化问题解答 | |
| 6、Western Blotting 操作步骤 | |
| 7、Western Blotting 问题解答 | |
| 8、关于肽链的设计 | |
| 9、多肽的溶解与保存 | |
| 10、酶标抗体效价测定程序 | |
